Xiayun He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiayun He has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Chaosu Hu
Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
55 shared publications - Tingting Xu
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai 200032, China
49 shared publications - Xueguan Lu
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Clinical Research Center for Radiation Oncology, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China
49 shared publications - Qinghai Ji
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
48 shared publications - Xiaomin Ou
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
48 shared publications - Dan Ou
Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China
40 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Wiley in Advanced Science
PLOD1 Catalytic Activity Stabilizes ENO1 by Limiting FBXW7‐dependent Degradation to Promote Glycolysis and TMZ Resistance in Glioblastoma
Acquired resistance to temozolomide (TMZ) remains a major therapeutic challenge in glioblastoma (GBM), with metabolic reprogramming emerging as a critical driver of treatment failure. Procollagen lysyl hydroxylase 1 (PLOD1) is identified as a key regulator of adaptive metabolic remodeling in TMZ‐resistant GBM. Elevated PLOD1 promotes a hyper‐glycolytic phenotype by maintaining the stability of the glycolytic enzyme alpha‐enolase (ENO1). Mechanistically, PLOD1 catalytic activity increases an ENO1‐associated hydroxylation signal, promotes ENO1 stability, and limits FBXW7‐dependent ubiquitination and proteasomal degradation. Structural and functional analyses reveal that the central Ndst region of PLOD1 mediates substrate interaction, whereas its catalytic domain is required for ENO1 stabilization and downstream metabolic regulation. Clinically, PLOD1 and ENO1 expression levels are positively correlated in GBM specimens, and their co‐expression is associated with unfavorable patient outcomes. In xenograft models, inhibition of the PLOD1‐ENO1 axis suppresses tumor progression and enhances TMZ responsiveness. These findings establish the PLOD1‐FBXW7‐ENO1 regulatory axis as a critical mediator of GBM metabolic adaptation and therapeutic resistance, highlighting its potential as a prognostic biomarker and therapeutic target.
- 27 September 2026
- Published by Wiley in Advanced Science
Open AccessPLOD1 Catalytic Activity Stabilizes ENO1 by Limiting FBXW7‐dependent Degradation to Promote Glycolysis and TMZ Resistance in Glioblastoma
Acquired resistance to temozolomide (TMZ) remains a major therapeutic challenge in glioblastoma (GBM), with metabolic reprogramming emerging as a critical driver of treatment failure. Procollagen lysyl hydroxylase 1 (PLOD1) is identified as a key regulator of adaptive metabolic remodeling in TMZ‐resistant GBM. Elevated PLOD1 promotes a hyper‐glycolytic phenotype by maintaining the stability of the glycolytic enzyme alpha‐enolase (ENO1). Mechanistically, PLOD1 catalytic activity increases an ENO1‐associated hydroxylation signal, promotes ENO1 stability, and limits FBXW7‐dependent ubiquitination and proteasomal degradation. Structural and functional analyses reveal that the central Ndst region of PLOD1 mediates substrate interaction, whereas its catalytic domain is required for ENO1 stabilization and downstream metabolic regulation. Clinically, PLOD1 and ENO1 expression levels are positively correlated in GBM specimens, and their co‐expression is associated with unfavorable patient outcomes. In xenograft models, inhibition of the PLOD1‐ENO1 axis suppresses tumor progression and enhances TMZ responsiveness. These findings establish the PLOD1‐FBXW7‐ENO1 regulatory axis as a critical mediator of GBM metabolic adaptation and therapeutic resistance, highlighting its potential as a prognostic biomarker and therapeutic target.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
Supplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
Supplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
Supplementary figures and legends
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
Supplementary figures and legends
- Open Access
- 4 March 2025
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 151 (3) , 1-10
Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults
Purpose This study aims to evaluate the efficacy and toxicity of the two induction chemotherapy (IC) regimens (TPF: docetaxel, cisplatin and 5-fluorouracil, and PF: cisplatin and 5-fluorouracil) combined with radiotherapy in young and middle aged patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Methods A retrospective analysis was conducted on 329 cases with stage III-IVA nasopharyngeal carcinoma from September 2005 to February 2017. Of the 329 cases, 253 cases underwent TPF (docetaxel: 60 mg/m2 on day 1, cisplatin: 25 mg/m2 on days 1–3, 5-fluorouracil: 500 mg/m2 on days 1–5, intravenous 120-h infusion), while 76 cases received the PF regimen (cisplatin: 25 mg/m2 on days 1–3, 5-fluorouracil: 500 mg/m2 on days 1–5, intravenous 120-h infusion) every 3 weeks. Radiotherapy was administered after IC with or without concurrent chemotherapy. The survival rates were assessed by Kaplan–Meier analysis, and the survival curves were compared using a log‑rank test. Results The 5-year and 8-year overall survival (OS) rates of the PF group and TPF group were 80.1% and 72.1%, 87.3% and 78.4% respectively (p = 0.405). There were no statistical differences in regional recurrence-free survival (RRFS) and distant metastasis-free survival (DMFS) rates between PF and TPF groups(p = 0.585 and 0.500, respectively).The 5-year and 8-year estimated local recurrence free survival (LRFS) rates for patients in PF and TPF group were 91.1% and 78.0%, 96.2% and 93.7%, respectively (p = 0.026). Moreover, The OS, LRFS, RRFS and DMFS rates were comparable between the non CCRT or CCRT subgroup (p = 0.542, 0.319, 0.070, 0.986, respectively). Compared with PF group, the TPF group significantly increased the occurrence of grade 3 or 4 neutropenia and leukopenia (p < 0.001). Conclusion PF and TPF followed by radiotherapy with or without concurrent chemotherapy performed encouraging anti-tumor effects in LA-NPC, there was no statistical significance in 5-year and 8-year OS, RRFS, and DMFS rates between two chemotherapy regimens. Compared with PF, TPF induction chemotherapy achieved more satisfactory LRFS rate in LA-NPC with acceptable toxicity.
- 4 March 2025
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 151 (3) , 1-10
Open AccessLong-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults
Purpose This study aims to evaluate the efficacy and toxicity of the two induction chemotherapy (IC) regimens (TPF: docetaxel, cisplatin and 5-fluorouracil, and PF: cisplatin and 5-fluorouracil) combined with radiotherapy in young and middle aged patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Methods A retrospective analysis was conducted on 329 cases with stage III-IVA nasopharyngeal carcinoma from September 2005 to February 2017. Of the 329 cases, 253 cases underwent TPF (docetaxel: 60 mg/m2 on day 1, cisplatin: 25 mg/m2 on days 1–3, 5-fluorouracil: 500 mg/m2 on days 1–5, intravenous 120-h infusion), while 76 cases received the PF regimen (cisplatin: 25 mg/m2 on days 1–3, 5-fluorouracil: 500 mg/m2 on days 1–5, intravenous 120-h infusion) every 3 weeks. Radiotherapy was administered after IC with or without concurrent chemotherapy. The survival rates were assessed by Kaplan–Meier analysis, and the survival curves were compared using a log‑rank test. Results The 5-year and 8-year overall survival (OS) rates of the PF group and TPF group were 80.1% and 72.1%, 87.3% and 78.4% respectively (p = 0.405). There were no statistical differences in regional recurrence-free survival (RRFS) and distant metastasis-free survival (DMFS) rates between PF and TPF groups(p = 0.585 and 0.500, respectively).The 5-year and 8-year estimated local recurrence free survival (LRFS) rates for patients in PF and TPF group were 91.1% and 78.0%, 96.2% and 93.7%, respectively (p = 0.026). Moreover, The OS, LRFS, RRFS and DMFS rates were comparable between the non CCRT or CCRT subgroup (p = 0.542, 0.319, 0.070, 0.986, respectively). Compared with PF group, the TPF group significantly increased the occurrence of grade 3 or 4 neutropenia and leukopenia (p < 0.001). Conclusion PF and TPF followed by radiotherapy with or without concurrent chemotherapy performed encouraging anti-tumor effects in LA-NPC, there was no statistical significance in 5-year and 8-year OS, RRFS, and DMFS rates between two chemotherapy regimens. Compared with PF, TPF induction chemotherapy achieved more satisfactory LRFS rate in LA-NPC with acceptable toxicity.
- Open Access
- 27 January 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (4) , 933-939
Pretreatment FDG PET in prognosis of locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy
Objectives: We aimed to investigate the long-term survival benefit of PET/CT compared with the routine examination (chest CT, abdominal enhanced CT and emission computed tomography (ECT)) for locally advanced nasopharyngeal carcinoma (NPC) before treatment.
- 27 January 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (4) , 933-939
Open AccessPretreatment FDG PET in prognosis of locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy
Objectives: We aimed to investigate the long-term survival benefit of PET/CT compared with the routine examination (chest CT, abdominal enhanced CT and emission computed tomography (ECT)) for locally advanced nasopharyngeal carcinoma (NPC) before treatment.
- Open Access
- 1 February 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (4) , e6578
Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non‐metastatic stage T4 nasopharyngeal carcinoma in IMRT era
Purpose: Intensity‐modulated radiotherapy (IMRT) combined with concurrent chemotherapy is deemed as the mainstay treatment in locoregionally advanced nasopharyngeal carcinoma (NPC). Nevertheless, the tolerance of severe acute toxicity of concurrent chemotherapy was unsatisfied. In addition, T4 is the predicting factor of poor prognosis for NPC patients. In this retrospective analysis, the long‐term outcomes IMRT combined by induction chemotherapy deleting concurrent chemotherapy with or without adjuvant chemotherapy for T4 non‐metastatic NPC were analyzed.Materials and Methods: From January 2005 to November 2016, a total of 145 biopsy‐proven non‐metastatic T4 NPC was treated with IMRT combined by induction chemotherapy with or without adjuvant chemotherapy. The survival and side effects of the patients were analyzed.Results: Median follow‐up time was 74 months (ranges, 8–186 months). 10.0%, 61.3%, 27.3%, and 1.3% developed grade 1, 2, 3, and 4 mucositis during IMRT, respectively. 5.5% and 2.0% patients experienced grade 1 and 2 nausea and vomiting; no patients developed grade 3 or 4 nausea and vomiting. Of 145 patients enrolled, 5‐year and 10‐year overall survival(OS) rates were 73.7% and 53.9%, local progression‐free survival(LPFS) rates were 86.1% and 71.6%, regional progression‐free survival(RPFS) rates were 96.7% and 92.8%, distant metastasis‐free survival (DMFS) rates were 86.7%, 78.2%, respectively. At the last follow‐up, five patients developed cranial nerve injury, one patient developed mandibular bone necrosis, four patients developed temporal lobe injury, four patients developed nasopharyngeal massive hemorrhage (three cases after recurrence and one case without recurrence), and five patients developed second primary tumor.Conclusion: The survival outcomes of treating T4 NPC IMRT combined by induction chemotherapy deleting concurrent chemotherapy with or without adjuvant chemotherapy are encouraging. Moreover, mucosal reaction, nausea, and vomiting reaction were reduced during IMRT.
- 1 February 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (4) , e6578
Open AccessDeletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non‐metastatic stage T4 nasopharyngeal carcinoma in IMRT era
Purpose: Intensity‐modulated radiotherapy (IMRT) combined with concurrent chemotherapy is deemed as the mainstay treatment in locoregionally advanced nasopharyngeal carcinoma (NPC). Nevertheless, the tolerance of severe acute toxicity of concurrent chemotherapy was unsatisfied. In addition, T4 is the predicting factor of poor prognosis for NPC patients. In this retrospective analysis, the long‐term outcomes IMRT combined by induction chemotherapy deleting concurrent chemotherapy with or without adjuvant chemotherapy for T4 non‐metastatic NPC were analyzed.Materials and Methods: From January 2005 to November 2016, a total of 145 biopsy‐proven non‐metastatic T4 NPC was treated with IMRT combined by induction chemotherapy with or without adjuvant chemotherapy. The survival and side effects of the patients were analyzed.Results: Median follow‐up time was 74 months (ranges, 8–186 months). 10.0%, 61.3%, 27.3%, and 1.3% developed grade 1, 2, 3, and 4 mucositis during IMRT, respectively. 5.5% and 2.0% patients experienced grade 1 and 2 nausea and vomiting; no patients developed grade 3 or 4 nausea and vomiting. Of 145 patients enrolled, 5‐year and 10‐year overall survival(OS) rates were 73.7% and 53.9%, local progression‐free survival(LPFS) rates were 86.1% and 71.6%, regional progression‐free survival(RPFS) rates were 96.7% and 92.8%, distant metastasis‐free survival (DMFS) rates were 86.7%, 78.2%, respectively. At the last follow‐up, five patients developed cranial nerve injury, one patient developed mandibular bone necrosis, four patients developed temporal lobe injury, four patients developed nasopharyngeal massive hemorrhage (three cases after recurrence and one case without recurrence), and five patients developed second primary tumor.Conclusion: The survival outcomes of treating T4 NPC IMRT combined by induction chemotherapy deleting concurrent chemotherapy with or without adjuvant chemotherapy are encouraging. Moreover, mucosal reaction, nausea, and vomiting reaction were reduced during IMRT.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
The Differential Expression of Various Genes between the Resistant and Sensitive Groups
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
The Differential Expression of Various Genes between the Resistant and Sensitive Groups
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)